2,178 Shares in Novo Nordisk A/S (NYSE:NVO) Acquired by Nabity Jensen Investment Management Inc

Nabity Jensen Investment Management Inc acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,178 shares of the company’s stock, valued at approximately $259,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Natixis Advisors LLC boosted its position in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares in the last quarter. Zions Bancorporation N.A. raised its position in shares of Novo Nordisk A/S by 57.0% in the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after purchasing an additional 6,726 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Novo Nordisk A/S by 14.8% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after buying an additional 37,346 shares in the last quarter. Private Wealth Partners LLC lifted its position in Novo Nordisk A/S by 155.1% in the 3rd quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock valued at $3,953,000 after acquiring an additional 20,188 shares in the last quarter. Finally, MayTech Global Investments LLC boosted its position in shares of Novo Nordisk A/S by 14.1% during the third quarter. MayTech Global Investments LLC now owns 254,552 shares of the company’s stock valued at $30,309,000 after buying an additional 31,475 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $110.77 on Monday. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15. The stock has a market cap of $497.08 billion, a price-to-earnings ratio of 35.85, a price-to-earnings-growth ratio of 1.41 and a beta of 0.40. The firm has a 50-day moving average of $111.31 and a two-hundred day moving average of $127.07. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Analyst Ratings Changes

A number of research firms have commented on NVO. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $150.40.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.